#Gilead Sciences Sees Growth in HIV Sector
Gilead delivered another quarter of HIV-led growth, reinforcing the durability of its core franchise while signaling a broader transition toward a diversified platform biotech model. The results suggest the company is successfully converting its dominant HIV position into a long-duration growth engine supported by prevention, oncology, and immunology expansion.
The strongest strategic signal came from HIV prevention. Yeztugo’s launch trajectory, combined with accelerating Descovy demand, indicates Gilead is expanding the overall PrEP market rather than merely defending existing share. High reimbursement access, low patient copays, and growing adoption among treatment-naïve users could improve persistence rates and create a more recurring revenue profile over time. Management’s decision to raise Yeztugo guidance to $1 billion for 2026 suggests commercial uptake is materially exceeding internal expectations.
BIC/LEN may prove equally important to the long-term investment case. The combination positions Gilead to extend HIV treatment leadership beyond Biktarvy by targeting switch patients and people on complex regimens. That potentially reduces future competitive erosion risk while supporting franchise durability well into the next decade. The pending FDA review also reinforces management’s strategy of continuously refreshing the HIV portfolio before major exclusivity cliffs emerge.
Outside HIV, Gilead is increasingly deploying capital to reshape its future growth mix. The acquisitions of Arcellx, Tubulis, and Ouro Medicines indicate management is prioritizing platform depth in oncology and autoimmune disease despite near-term earnings dilution. That raises execution risk, particularly as Cell Therapy sales remain under competitive pressure, but it also broadens the company’s exposure to higher-growth therapeutic categories. Trodelvy’s expansion into earlier-line breast cancer settings and the planned anito-cel launch could become important catalysts in shifting investor perception away from Gilead as primarily a mature HIV company.
#Q1 Revenue Reaches $7 Billion as Guidance Increases
Gilead reported first quarter 2026 revenue of $7.0 billion, up 4% year over year, while total product sales increased 5% to $6.9 billion. Product sales excluding Veklury rose 8% to $6.8 billion. HIV product sales increased 10% to $5.0 billion, led by Biktarvy sales of $3.4 billion, up 7%, and Descovy sales of $807 million, up 38%. Yeztugo generated $166 million in quarterly sales, increasing 72% sequentially. Trodelvy sales rose 37% to $402 million, while Livdelzi sales increased more than 230% year over year to $133 million.
Biktarvy maintained more than 52% U.S. HIV treatment market share during the quarter. Gilead stated that approximately 95% of eligible U.S. patients now have Yeztugo coverage, with approximately 95% of covered patients able to access the product with no copay obligation. The company increased full-year 2026 Yeztugo guidance to $1 billion.
Cell Therapy sales declined 12% to $407 million due to competitive pressure, while Veklury sales fell 52% to $144 million because of lower COVID-19 hospitalization rates. Product gross margin improved to 79.2% from 76.7% in the prior-year period. R&D expense remained approximately $1.4 billion, while SG&A expense increased to $1.5 billion due primarily to higher HIV promotional spending.
The company raised full-year 2026 product sales guidance to a range of $30.0 billion to $30.4 billion from prior guidance of $29.6 billion to $30.0 billion. Product sales excluding Veklury are now expected to range between $29.4 billion and $29.8 billion. However, GAAP diluted EPS guidance was revised to a projected loss of $3.25 to $2.85 per share due primarily to approximately $11.5 billion in anticipated acquired IPR&D charges and financing costs related to the Arcellx, Ouro Medicines, and Tubulis transactions.
Gilead completed the acquisition of Arcellx at $115 per share plus one contingent value right worth $5 per share, implying an equity value of approximately $7.8 billion. The company also announced definitive agreements to acquire Tubulis and Ouro Medicines. The Ouro framework agreement includes an upfront payment of $1.675 billion and up to $500 million in milestone payments shared equally with Galapagos. Both transactions remain subject to regulatory approvals and customary closing conditions.
The FDA accepted Gilead’s New Drug Application for BIC/LEN under priority review with a PDUFA target action date of August 27, 2026. The Biologics License Application for anito-cel in relapsed or refractory multiple myeloma was also accepted, with a PDUFA target action date of December 23, 2026.
The company ended the quarter with $8.6 billion in cash, cash equivalents, and marketable debt securities after repaying $2.8 billion of debt, paying $1.0 billion in dividends, and repurchasing $419 million of common stock. Operating cash flow totaled $2.5 billion during the quarter.
“Building on the strongest pipeline in Gilead’s history, we are adding potentially best-in-disease assets and platforms in oncology and inflammation from our acquisitions of Arcellx, Ouro Medicines and Tubulis.”
#Why This News Matters
Product sales excluding Veklury increased 8% year over year to $6.8 billion
HIV revenue rose 10% to $5.0 billion
Yeztugo generated $166 million in quarterly sales and guidance increased to $1 billion for 2026
Approximately 95% of eligible U.S. patients now have Yeztugo coverage
Biktarvy maintained more than 52% U.S. HIV treatment market share
Trodelvy sales climbed 37% to $402 million
Livdelzi sales exceeded $133 million with more than 50% second-line PBC market share
Full-year revenue guidance increased by $400 million
EPS guidance was reduced primarily due to approximately $11.5 billion in expected acquisition-related IPR&D charges
BIC/LEN and anito-cel both received FDA filing acceptance with 2026 PDUFA dates
#Strategic Takeaways for Investors
Gilead’s investment profile is increasingly tied to the durability and expansion potential of its HIV ecosystem. Yeztugo and BIC/LEN are strategically important because they extend the franchise into long-acting prevention and next-generation switch therapy categories that could support growth well beyond Biktarvy’s peak years. If adoption trends continue, investors may begin valuing the HIV portfolio less as a mature cash-flow business and more as a multi-cycle innovation platform.
At the same time, management is attempting to reposition Gilead as a broader oncology and immunology company through acquisitions and late-stage pipeline investment. That strategy could create long-term diversification benefits, but execution remains critical. Investors should monitor Trodelvy’s expansion into earlier-line breast cancer settings, commercialization progress for anito-cel, and whether recently acquired platforms generate clinically differentiated assets. The next 12 months will likely determine whether Gilead can successfully transition from a primarily HIV-focused business into a more diversified growth biotech with multiple commercial engines.
#About the Company
Gilead Sciences is a biotechnology company focused on antiviral medicines, oncology therapies, cell therapy, and inflammatory disease treatments. Its portfolio includes HIV therapies such as Biktarvy and Descovy, oncology products including Trodelvy and Yescarta, and liver disease treatments such as Livdelzi.
#FAQs for Retail Investors
#Why did Gilead lower EPS guidance despite raising revenue guidance?
The reduction primarily reflects anticipated acquisition-related IPR&D charges and financing costs tied to Arcellx, Ouro Medicines, and Tubulis rather than deterioration in the underlying business.
#Why is Yeztugo strategically important?
Yeztugo is the first twice-yearly injectable HIV prevention product and could materially expand the PrEP market through stronger adherence, persistence, and patient adoption.
#What is BIC/LEN and why does it matter?
BIC/LEN is an investigational once-daily HIV treatment combining bictegravir and lenacapavir. Gilead believes it could strengthen its leadership in the HIV switch market and support long-term franchise durability.
#What are the biggest oncology catalysts ahead?
Key catalysts include potential FDA decisions for Trodelvy in first-line metastatic triple-negative breast cancer and anito-cel in multiple myeloma, along with pipeline updates from Tubulis assets.
#What risks should investors monitor?
Key risks include integration execution from recent acquisitions, competitive pressure in Cell Therapy, regulatory outcomes, pricing headwinds, and commercialization performance for newly launched products.